Sen. Susan Collins (R-Maine) is the recipient of the ACR’s 2018 Award for Public Leadership in Rheumatology. Sen. Collins has championed several pieces of legislation that support rheumatologists and rheumatology patients, and she has taken part in multiple efforts to address ongoing concerns in rheumatology. “Sen. Collins has consistently worked both sides of the aisle…
Beth Jonas: Making a Difference in Training & Workforce Support
Early in her medical school career, Beth Jonas, MD, FACR, was fascinated by the multi-system and chronic nature of rheumatic diseases. The field of rheumatology offered her the chance to make long-term connections with the patients she cares for, and she says her early instincts have led her to a career that has not disappointed….
What the Election Means for Rheumatology
The 2018 U.S. midterm elections mobilized American voters, bringing more than 100 million people to the polls.1 It also brought the House of Representatives under the control of Democrats, while Republicans maintained control of the Senate, splitting the legislative branch between two parties. As the 116th Congress prepares to convene in January 2019, the ACR’s…
Quality Payment Program Year 3 Reporting Changes: What You Need to Know
The Centers for Medicare & Medicaid Services (CMS) released the final rule for the Quality Payment Program (QPP) year 3 (CY 2019) on Nov. 1, 2018. Below, we have compiled a list of key changes to ensure MIPS-eligible clinicians are accurately reporting for CY 2019: New MIPS-eligible clinician types: Physical therapist, occupational therapist, qualified speech-language…
FDA Approves Opioid Treatment
The FDA has approved the use of sublingual sufentanil (Dsuvia) to treat acute pain in adults in a medically supervised setting…
A Balancing Act: Tips to Ensure Optimal Screening & Treatment for Osteoporosis
Patients with rheumatic diseases may be undertreated for osteoporosis. To decrease fracture risk for at-risk patients, rheumatologists can engage patients in shared decision making with regular screening and education about treatment options…
Ustekinumab May Be Effective for Lupus
New research underscores the possibility that interleukin (IL) 12, IL-23 or both play roles in the immunopathology of SLE. In the study, when added to standard-of-care treatment for active SLE, ustekinumab demonstrated better efficacy than placebo and had a safety profile consistent with that of ustekinumab therapy in other diseases…
Final 2019 Physician Reimbursement Rule Released by CMS Includes Victories for Rheumatology
On Nov. 1, after months of advocacy efforts spearheaded by the ACR and others, the Centers for Medicare and Medicaid Services (CMS) released the CY 2019 Medicare physician fee schedule rule, and it included several victories for rheumatology. Upon initial review, it appears the CMS has taken into account the concerns expressed by the ACR and…
5-Year Data on Secukinumab in AS; Oliceridine Not Recommended for FDA Approval
In a long-term study, secukinumab proved safe and effective for treating ankylosing spondylitis…
Ixekizumab Improves Outcomes of Ankylosing Spondylitis
NEW YORK (Reuters Health)—Ixekizumab improves signs and symptoms in patients with radiographic axial spondyloarthritis (ankylosing spondylitis), according to results from the COAST-W study. “Ankylosing spondylitis is a chronic and debilitating disease, and I have a large number of patients who have failed TNF inhibitors,” says Dr. Atul Deodhar from Oregon Health and Science University, Portland….
- « Previous Page
- 1
- …
- 302
- 303
- 304
- 305
- 306
- …
- 816
- Next Page »